Acute HIV Infection & Seroconversion

1. Clinical Overview

Summary

Acute HIV infection, also known as Primary HIV Infection or Acute Retroviral Syndrome (ARS), represents the period immediately following HIV acquisition until the development of a stable "viral set point." [1] It typically occurs 2 to 4 weeks after exposure and is characterized by a high viral load and a transient, non-specific "mononucleosis-like" illness in 40-90% of patients. [2]

Diagnosis is critical because individuals are most infectious during this phase due to extremely high levels of viraemia in blood and genital secretions. [3] Furthermore, early initiation of Antiretroviral Therapy (ART) during this "window of opportunity" can preserve immune function, limit the size of the latent viral reservoir, and prevent onward transmission (U=U). [4] Diagnosis requires 4th-generation Ag/Ab immunoassays or HIV RNA PCR, as older antibody-only tests may be negative during the earliest stages. [5]

Key Facts

• The "Great Mimicker": Often misdiagnosed as infectious mononucleosis, influenza, or a "viral throat infection." A negative Monospot test in a patient with glandular fever-like symptoms should always trigger an HIV test. [2,6]
• The Highest Infectivity: Viral loads often exceed 10 million copies/mL during the acute phase, making the risk of transmission per act significantly higher than in chronic infection. [3]
• 4th Gen Testing: Modern tests detect the p24 antigen (which appears within 2 weeks) alongside antibodies (which appear within 3-4 weeks), shortening the "window period." [5]
• Immediate ART: Current guidelines recommend starting ART as soon as the diagnosis is made ("Rapid Start"), regardless of the CD4 count. [4,7]
• The "Eclipse Phase": The initial 7-10 days after infection where no current tests (including PCR) can reliably detect the virus. [1]

Clinical Pearls

The "Rash and Throat" Pearl: In a patient with a fever and sore throat, the presence of a non-pruritic maculopapular rash and shallow oral ulcers is highly suggestive of HIV seroconversion over EBV-related mononucleosis. [2,8]

The "Window Period" Tip: If the initial 4th-gen Ag/Ab test is negative but suspicion remains high, order an HIV RNA PCR. Viral nucleic acid is detectable approximately 5-7 days before p24 antigen. [1,5]

---

2. Epidemiology & Risk Factors

Incidence & Distribution

• Prevalence: Approximately 1.3 million new HIV infections occur globally each year. [9]
• The Missed Opportunity: Up to 75% of patients with acute HIV seek medical care for their symptoms, but the diagnosis is missed by clinicians in over half of these encounters. [10]
• Transmission Impact: It is estimated that 30-50% of new HIV transmissions originate from individuals who are in the acute phase of infection and unaware of their status. [3]

Risk Factors

---

3. Pathophysiology

1. Viral Entry and Seeding

HIV (most commonly HIV-1) crosses the mucosal barrier and infects local CD4+ T-cells and dendritic cells. The virus is then transported to regional lymph nodes, where massive replication occurs. [1,13]

2. Cytokine Storm

Within days, a systemic "burst" of viraemia occurs. The immune system's attempt to control this massive viral replication leads to an explosion of pro-inflammatory cytokines (TNF-α, IFN-γ, IL-6). This "cytokine storm" is responsible for the clinical symptoms of the acute retroviral syndrome. [1,14]

3. Gut-Associated Lymphoid Tissue (GALT) Depletion

Crucially, during the acute phase, a massive and irreversible depletion of CCR5+ memory CD4+ T-cells occurs in the GALT. This compromises gut barrier integrity ("leaky gut") and leads to chronic microbial translocation and systemic immune activation, which drives long-term disease progression. [13,15]

---

4. Clinical Presentation

Symptoms & Signs

Differential Diagnosis

• Infectious Mononucleosis (EBV): Usually lacks the rash and mucosal ulcers; Monospot/EBV serology positive.
• Secondary Syphilis: Rash involves palms/soles; positive RPR/TPPA.
• Acute CMV Infection: Similar to EBV; often in older or immunocompromised patients.
• Influenza / COVID-19: Primary respiratory symptoms (cough/congestion) are more prominent.

---

5. Investigations

1. Laboratory Screening

2. Baseline Tests (Post-Diagnosis)

• CD4 Count: Baseline for monitoring (often transiently low in acute phase).
• HIV Resistance Genotype: To guide ART selection (detects transmitted resistance). [7]
• STI Screen: Syphilis, Gonorrhoea, Chlamydia (high co-infection rates).
• Hepatitis Serology: Hep B and Hep C screening is mandatory. [7]

---

6. Management: The Acute HIV Algorithm

Management Flowchart (ASCII)

                  [SUSPECTED ACUTE HIV EXPOSURE / SYMPTOMS]
                                     |
              +----------------------v----------------------+
              |   4th GEN HIV Ag/Ab IMMUNOASSAY (p24 + Ab)  |
              +----------------------+----------------------+
                                     |
              /----------------------+----------------------\
      [POSITIVE]                                        [NEGATIVE]
             |                                              |
    +--------v--------+                      /--------------+--------------\
    | CONFIRM Dx      |              [HIGH CLINICAL SUSPICION?]         [LOW]
    | (Differentiation|                     |                               |
    |  Immunoassay)   |              +------v------+                 +------v------+
    +--------+--------+              | HIV RNA PCR |                 | REPEAT TEST |
             |                       +------+------+                 | @ 6 WEEKS   |
             |                              |                        +-------------+
             |               /--------------+--------------\
             |       [POSITIVE (> 10,000)]              [NEGATIVE]
             |               |                             |
             +---------------v-----------------------------v-------+
             |    IMMEDIATE MANAGEMENT (The "Rapid Start" Bundle)  |
             |    1. Counsel & Support (Mental Health/U=U)         |
             |    2. Baseline Bloods (Resistance/CD4/STIs)         |
             |    3. START ART (e.g., Biktarvy or Dovato)          |
             |    4. Partner Notification / Contact Tracing        |
             +-----------------------------------------------------+

1. Specific Emergency Treatment

• Immediate ART Initiation: Do not wait for resistance results if there are no signs of opportunistic infections. Early ART reduces the viral "set point" and preserves immune function. [4,17]
• Regimen Selection: Typically a single-tablet regimen (STR) containing an Integrase Inhibitor (INSTI) with a high genetic barrier (e.g., Bictegravir or Dolutegravir). [7]
• Symptomatic Relief: Antipyretics (Paracetamol) and hydration for the viral syndrome symptoms.

2. Public Health Actions

• Partner Notification: Identify and contact sexual partners from the last 3 months. Partners exposed in the last 72 hours may be eligible for PEP. [18]
• U=U Education: Counsel the patient that once the viral load is undetectable for 6 months, they cannot sexually transmit the virus. [19]

---

7. Complications

• Severe Neurological Involvement: Encephalitis, Guillain-Barré Syndrome, or Bell's Palsy. [16]
• Opportunistic Infections: Rare in the acute phase, but "Pneumocystis" pneumonia (PCP) or Oesophageal Candidiasis can occur due to the transient profound CD4 drop. [2]
• Immune Reconstitution Inflammatory Syndrome (IRIS): Can occur if ART is started in the presence of an undiagnosed OI.
• Mental Health Crisis: High risk of depression and anxiety following a new diagnosis.

---

8. Evidence & Landmark Trials

1. START Trial (PMID: 26192873): Definitively proved that starting ART immediately (CD4 > 500) reduces the risk of serious AIDS-related and non-AIDS-related events by 57% compared to deferring therapy. [4]
2. HPTN 052 (PMID: 21767103): Landmark study showing that early ART reduces the risk of sexual transmission to HIV-negative partners by 96% ("Treatment as Prevention"). [3]
3. PARTNER 1 & 2 Trials (PMID: 31056293): Confirmed zero cases of sexual transmission in serodifferent couples (both MSM and heterosexual) when the HIV-positive partner had a suppressed viral load. [19]
4. TEMPRANO Trial (PMID: 26192874): Performed in West Africa; confirmed the benefits of early ART even in resource-limited settings. [17]
5. RIVER Trial (PMID: 32278550): Investigated "Kick and Kill" strategies to eliminate the latent reservoir; currently, ART remains the only standard of care for reservoir management. [20]

---

9. Single Best Answer (SBA) Questions

Question 1

A 26-year-old male presents to the Emergency Department with a 5-day history of fever, sore throat, and a non-itchy rash on his chest. He also reports painful ulcers in his mouth. He mentions a new sexual partner three weeks ago with whom he did not use condoms. A Monospot test is negative. What is the most appropriate next step?

• A) Reassure the patient it is a viral URTI and prescribe paracetamol
• B) Perform a 4th-generation HIV Ag/Ab test and HIV RNA PCR
• C) Start a 5-day course of Prednisolone for suspected glandular fever
• D) Prescribe a course of Penicillin V for streptococcal pharyngitis
• E) Repeat the Monospot test in 1 week
• Answer: B. The clinical triad of fever, pharyngitis, and rash with shallow ulcers + negative Monospot + recent risk is highly suggestive of acute HIV. Combined Ag/Ab and PCR are needed for maximum sensitivity in early infection.

Question 2

In the "Eclipse Phase" of HIV infection, which of the following statements is true?

• A) p24 antigen is detectable but antibodies are not
• B) HIV RNA is detectable but p24 antigen is not
• C) Both p24 and HIV RNA are detectable
• D) Neither p24 antigen nor HIV RNA are detectable
• E) The patient is not yet infectious to others
• Answer: D. The eclipse phase is the first 7-10 days after infection where the virus is replicating but levels are below the threshold of detection for current assays.

Question 3

Which laboratory finding is most characteristic of the earliest stage of HIV seroconversion (Fiebig Stage II)?

• A) HIV RNA positive, p24 antigen negative, Antibody negative
• B) HIV RNA positive, p24 antigen positive, Antibody negative
• C) HIV RNA positive, p24 antigen positive, Antibody positive
• D) HIV RNA negative, p24 antigen positive, Antibody negative
• E) HIV RNA positive, p24 antigen negative, Antibody positive
• Answer: B. Fiebig Stage I is RNA only. Stage II is RNA + p24 antigen but still antibody negative.

Question 4

A patient is diagnosed with acute HIV. He is distraught and worried about passing it to his long-term partner. His viral load is 2,000,000 copies/mL. Which of the following is the most evidence-based advice?

• A) He is not infectious because the infection is so new
• B) He should wait for his CD4 count to drop below 350 before starting ART
• C) He is currently at his most infectious stage due to extremely high viraemia
• D) Condoms are not necessary if he feels well
• E) ART should be delayed until a resistance genotype is available
• Answer: C. Acute HIV is the period of highest transmissibility. Immediate ART is recommended to reduce viral load and transmission risk.

Question 5

What is the primary pathophysiology behind the systemic symptoms seen in Acute Retroviral Syndrome?

• A) Direct destruction of all CD4 cells by the virus
• B) Bacterial translocation from the gut due to GALT depletion
• C) A cytokine storm triggered by massive viral replication
• D) Secondary infection with opportunists like CMV
• E) Autoimmune reaction against the pancreas
• Answer: C. The flu-like symptoms are driven by the massive release of inflammatory cytokines (TNF-α, IFNs) in response to peak viraemia.

---

10. Patient Explanation

"Acute HIV infection is the early stage of HIV, occurring shortly after a person has been exposed to the virus. Think of it like the body's 'first reaction' to the virus. Many people experience a flu-like illness with fever, sore throat, swollen glands, and a rash. It is often mistaken for a common cold or glandular fever.

This stage is very important for two reasons. First, the amount of virus in the blood is extremely high, meaning it is very easy to pass the virus to others during this time. Second, starting treatment immediately—even before your immune system is damaged—is the best way to protect your long-term health. Modern HIV treatment is just one pill a day, has very few side effects, and allows people with HIV to live long, healthy lives. Once the treatment brings the virus to 'undetectable' levels, you cannot pass it on to sexual partners (U=U)."

---

11. References

1. Ananworanich J, et al. Acute HIV infection. Curr Opin HIV AIDS. 2015;10(3):143-8. [PMID: 25767936]
2. Robb ML, et al. Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand. N Engl J Med. 2016;374(21):2013-23. [PMID: 27192528]
3. Cohen MS, et al. Prevention of HIV-1 Infection with Early Antiretroviral Therapy. N Engl J Med. 2011;365(6):493-505. [PMID: 21767103]
4. INSIGHT START Study Group. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015;373(9):795-807. [PMID: 26192873]
5. Branson BM, Stekler JD. Detection of Acute HIV Infection: We Can't Close the Gap If We Don't Open Our Eyes. J Infect Dis. 2012;205(3):351-3. [PMID: 22210874]
6. Daar ES, et al. Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network. Ann Intern Med. 2001;134(1):25-9. [PMID: 11177330]
7. BHIVA. Guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2022. [Online]
8. Lapins J, et al. Skin and mucosal characteristics of primary HIV-1 infection. AIDS. 1997;11(1):67-70. [PMID: 9110078]
9. UNAIDS. Global HIV & AIDS statistics — 2023 fact sheet. [Online]
10. Sudarshi D, et al. Missed opportunities for diagnosing primary HIV infection. Sex Transm Infect. 2008;84(1):14-6. [PMID: 17933923]
11. Patel P, et al. Estimating per-act HIV transmission risk: a systematic review. AIDS. 2014;28(10):1509-19. [PMID: 24809629]
12. Galvin SR, Cohen MS. The mechanisms of transmission of HIV-1. Nat Rev Microbiol. 2004;2(1):33-42. [PMID: 15035007]
13. McMichael AJ, et al. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol. 2010;10(1):11-23. [PMID: 20029444]
14. Stacey AR, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute HIV-1 infection. PLOS Pathog. 2009;5(3):e1000340. [PMID: 19325872]
15. Brenchley JM, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12(12):1365-71. [PMID: 17115046]
16. Hellmuth J, et al. Neurological Signs and Symptoms During Acute HIV Infection. J Infect Dis. 2016;214(11):1649-56. [PMID: 27601618]
17. TEMPRANO ANRS 12136 Study Group. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med. 2015;373(9):808-22. [PMID: 26192874]
18. NICE Guideline NG189. HIV testing: encouraging people to test. 2020.
19. Rodger AJ, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet. 2019;393(10189):2428-38. [PMID: 31056293]
20. Fidler S, et al. Antiretroviral therapy alone versus antiretroviral therapy with a therapeutic vaccine and a chidamide (RIVER): a phase 2, randomised, open-label, multicentre, proof-of-concept trial. Lancet. 2020;395(10227):888-98. [PMID: 32171411]

---

Last Updated: 2026-01-04 | MedVellum Editorial Team | Status: Gold Standard (V4)